KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Medtronic (MDT) Restructuring Costs (2016 - 2026)

Medtronic (MDT) has disclosed Restructuring Costs for 14 consecutive years, with $77.0 million as the latest value for Q1 2026.

  • Quarterly Restructuring Costs rose 79.07% to $77.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $282.0 million through Jan 2026, down 35.17% year-over-year, with the annual reading at $267.0 million for FY2025, 18.14% up from the prior year.
  • Restructuring Costs hit $77.0 million in Q1 2026 for Medtronic, up from $13.0 million in the prior quarter.
  • In the past five years, Restructuring Costs ranged from a high of $300.0 million in Q2 2023 to a low of $13.0 million in Q4 2025.
  • Historically, Restructuring Costs has averaged $93.2 million across 5 years, with a median of $62.0 million in 2024.
  • Biggest five-year swings in Restructuring Costs: skyrocketed 550.0% in 2023 and later tumbled 56.67% in 2025.
  • Year by year, Restructuring Costs stood at $30.0 million in 2022, then skyrocketed by 33.33% to $40.0 million in 2023, then dropped by 25.0% to $30.0 million in 2024, then crashed by 56.67% to $13.0 million in 2025, then skyrocketed by 492.31% to $77.0 million in 2026.
  • Business Quant data shows Restructuring Costs for MDT at $77.0 million in Q1 2026, $13.0 million in Q4 2025, and $45.0 million in Q3 2025.